Pharmacological management of co-morbid obstructive sleep apnoea and insomnia.
Emma ThomasGorica MicicRobert AdamsDanny J EckertPublished in: Expert opinion on pharmacotherapy (2024)
There are multiple promising emerging therapies, but clinical trial data specifically in COMISA populations are lacking. This is a priority for future investigation to inform development of evidence-based guidelines. Pharmacotherapies, particularly for insomnia, do not target the underlying causes of the disorder thus, are indicated for short-term use only and should remain second line. Future multidisciplinary research should be directed toward the multifactorial nature of COMISA and the challenges of adapting COMISA treatment in clinical practice and overcoming the practical barriers that health-care providers and consumers encounter.